中国临床实用医学
中國臨床實用醫學
중국림상실용의학
CHINA CLINICAL PRACTICAL MEDICINE
2009年
6期
83-84
,共2页
吴冬%李先明%李子煌%杨东%闫茂生%徐钢
吳鼕%李先明%李子煌%楊東%閆茂生%徐鋼
오동%리선명%리자황%양동%염무생%서강
神经胶质瘤%放射治疗%三维适彤放射治疗
神經膠質瘤%放射治療%三維適彤放射治療
신경효질류%방사치료%삼유괄동방사치료
Glioma%Radiotherapy%Three-dimensional conformal radiotherapy
目的 探讨脑胶质瘤术后三维适形放射治疗的临床疗效.方法 58例脑胶质瘤患者(WHO Ⅰ级4例,Ⅱ级8例,Ⅲ级26例,Ⅳ级20例)术后接受三维适形放射治疗,治疗剂量56~60 Gy/28~30次/5~6周.中位随访期27个月(13~42个月).结果 完全缓解:13.8%(8/58),部分缓解:24.1%(14/58),无进展:58.6%(34/58),进展:3.4%(2/58),总有效率(CR+PR):37.9%(22/58).6个月、1年、2年生存率分别为94.3%、78.5%、53.9%.全组患者1年、2年及3年生存率分别为94.8%、81.3%及74.1%.结论 三维适形放射治疗对脑胶质瘤术后患者有较高的肿瘤局部控制率及生存率.
目的 探討腦膠質瘤術後三維適形放射治療的臨床療效.方法 58例腦膠質瘤患者(WHO Ⅰ級4例,Ⅱ級8例,Ⅲ級26例,Ⅳ級20例)術後接受三維適形放射治療,治療劑量56~60 Gy/28~30次/5~6週.中位隨訪期27箇月(13~42箇月).結果 完全緩解:13.8%(8/58),部分緩解:24.1%(14/58),無進展:58.6%(34/58),進展:3.4%(2/58),總有效率(CR+PR):37.9%(22/58).6箇月、1年、2年生存率分彆為94.3%、78.5%、53.9%.全組患者1年、2年及3年生存率分彆為94.8%、81.3%及74.1%.結論 三維適形放射治療對腦膠質瘤術後患者有較高的腫瘤跼部控製率及生存率.
목적 탐토뇌효질류술후삼유괄형방사치료적림상료효.방법 58례뇌효질류환자(WHO Ⅰ급4례,Ⅱ급8례,Ⅲ급26례,Ⅳ급20례)술후접수삼유괄형방사치료,치료제량56~60 Gy/28~30차/5~6주.중위수방기27개월(13~42개월).결과 완전완해:13.8%(8/58),부분완해:24.1%(14/58),무진전:58.6%(34/58),진전:3.4%(2/58),총유효솔(CR+PR):37.9%(22/58).6개월、1년、2년생존솔분별위94.3%、78.5%、53.9%.전조환자1년、2년급3년생존솔분별위94.8%、81.3%급74.1%.결론 삼유괄형방사치료대뇌효질류술후환자유교고적종류국부공제솔급생존솔.
Objective To investigate the therapeutic effects of postoperative three2 dimensional confor-mal radiotherapy (3DCRT) for glioma. Methods Fifty-eight patients with glioma were treated by 3DCRT after operation with a dose of 56~60 Gy for 28~30 times and 5~6 weeks. According to WHO classification system, there were 4 cases with grade Ⅰ,8 with grade Ⅱ,26 with grade Ⅲ and 20 with grade Ⅳ. The median time of fol-low-up was 27 months(13~42 months). Results The complete response (CR) rate was13.8% (8/58) and partial response(PR) rate was24.1% (14/58). Stable disease (SD) was 58.6% (34/58) and progressive dis-ease(PD) was 3.4% (2/58). So the objective response rate (CR + PR) was 37.9% (22/58). The 1-year, 2-year and 3-year survival rates were 94.8%, 81.3%, 74.1% respectively. Conclusion 3DCRT is effective in the treatment of glioma after operation, and may lead to higher local control rate and survival.